Core Viewpoint - Shenzhou Cell (688520.SH) reported a significant decline in revenue and net profit for Q3 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for Q3 2025 was 340 million yuan, representing a year-on-year decrease of 46.25% [1] - The net profit attributable to shareholders of the listed company was -217 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -164 million yuan [1]

Financial Performance - The company's operating revenue for the third quarter was ¥339,860,646.36, a decrease of 46.25% compared to the same period last year[3]. - The total profit for the third quarter was -¥217,421,450.38, with a year-to-date total profit of -¥251,279,601.67[3]. - The net profit attributable to shareholders for the third quarter was -¥216,901,236.46, and -¥250,672,332.75 year-to-date[3]. - Total operating revenue for the first three quarters of 2025 was approximately ¥1.31 billion, a decrease of 32.3% compared to ¥1.94 billion in the same period of 2024[16]. - Net profit for the first three quarters of 2025 was a loss of approximately ¥251.28 million, compared to a profit of ¥150.41 million in 2024[17]. - The company recorded a total comprehensive loss of approximately ¥251.19 million in 2025, compared to a total comprehensive income of ¥150.44 million in 2024[17]. Research and Development - Research and development expenses totaled ¥203,990,325.36 for the quarter, accounting for 60.02% of operating revenue, an increase of 25.99 percentage points[4]. - Research and development expenses for the first three quarters of 2025 were approximately ¥581.82 million, a decrease of 13.3% from ¥671.79 million in 2024[16]. Assets and Liabilities - Total assets increased to ¥3,761,436,578.09, representing a 14.54% increase from the end of the previous year[4]. - The company's current assets totaled CNY 1,826,472,317.93, up from CNY 1,460,622,848.37 in the previous period, reflecting a growth of approximately 25.1%[12][13]. - Total liabilities reached CNY 3,816,211,088.58, compared to CNY 3,149,055,574.41, reflecting an increase of approximately 21.2%[14]. - The company's short-term borrowings surged to CNY 1,762,437,408.90 from CNY 1,077,987,553.63, a significant increase of about 63.5%[13][14]. - The total equity attributable to shareholders decreased to CNY -48,211,427.97 from CNY 140,896,888.73, indicating a decline in shareholder equity[14]. - The total liabilities to equity ratio has increased, indicating a higher leverage position for the company compared to the previous period[14]. Cash Flow - The cash flow from operating activities for the year-to-date was -¥306,820,436.08[4]. - The company reported a net cash outflow from operating activities of approximately ¥306.82 million in 2025, down from a cash inflow of ¥189.69 million in 2024[19]. - Cash inflow from investment activities was approximately ¥1.13 billion in 2025, compared to ¥752.09 million in 2024[19]. - Net cash inflow from financing activities was approximately ¥736.77 million in 2025, significantly higher than ¥159.75 million in 2024[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,749[9]. - The largest shareholder, Lhasa Ailike Investment Consulting Co., Ltd., held 60.90% of the shares[9]. Earnings Per Share - The company reported a basic earnings per share of -¥0.50 for the third quarter and -¥0.60 year-to-date[3]. - Basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.60, compared to ¥0.34 in 2024[17]. Sales and Revenue Decline - The company experienced a decline in sales revenue due to price reductions of its core product, Anjiajin®[7]. - Total operating costs increased to approximately ¥1.49 billion in 2025, up 2.2% from ¥1.46 billion in 2024[16]. Cash and Cash Equivalents - Cash and cash equivalents increased to CNY 396,498,224.09 from CNY 314,933,923.79, representing a rise of about 26%[12]. - Cash and cash equivalents at the end of the third quarter of 2025 totaled approximately ¥396.50 million, an increase from ¥340.44 million at the end of the same period in 2024[20]. Inventory and Accounts Receivable - Accounts receivable rose to CNY 688,905,342.85, compared to CNY 649,386,298.44, indicating an increase of approximately 6.1%[12]. - Inventory levels increased to CNY 326,970,398.21 from CNY 259,486,715.96, marking a growth of around 26%[12][13]. Non-Current Assets - The company reported a total non-current asset value of CNY 1,934,964,260.16, up from CNY 1,823,373,569.25, showing an increase of approximately 6.1%[13].

Group 1 - The core point of the article is that Shenzhou Cell reported a significant decline in revenue and incurred net losses in the third quarter and the first three quarters of the year [1] Group 2 - In the third quarter, the company's revenue was 340 million yuan, representing a year-on-year decrease of 46.25% [1] - The net profit for the third quarter was a loss of 217 million yuan [1] - For the first three quarters, the total revenue was 1.312 billion yuan, showing a year-on-year decline of 32.27% [1] - The net profit for the first three quarters was a loss of 251 million yuan [1]

Group 1 - The core viewpoint of the news is that Shenzhou Cell has experienced fluctuations in its stock price and trading volume, with a notable increase of 48.91% year-to-date, but a decline of 36.49% over the past 60 days [1] - As of October 20, Shenzhou Cell's stock price was 53.95 CNY per share, with a market capitalization of 24.026 billion CNY and a trading volume of 86.5076 million CNY [1] - The company has seen net outflows of main funds amounting to 595,100 CNY, with significant buying and selling activity from large orders [1] Group 2 - Shenzhou Cell operates in the biopharmaceutical sector, focusing on the research and commercialization of biological drugs for various diseases, including cancer and autoimmune diseases [2] - For the first half of 2025, Shenzhou Cell reported a revenue of 972 million CNY, a year-on-year decrease of 25.50%, and a net profit attributable to shareholders of -33.7711 million CNY, a decline of 126.87% [2] - The number of shareholders decreased by 12.74% to 9,754, while the average circulating shares per person increased by 14.60% to 45,656 shares [2]

Core Insights - The company Shenzhou Cell (688520.SH) reported a significant decline in its financial performance for the first half of 2025, with a revenue of 972 million yuan, representing a year-on-year decrease of 25.50% [1][3]. - The net profit attributable to shareholders was -33.77 million yuan, indicating a substantial loss compared to a profit of 125.71 million yuan in the same period last year, marking a decrease of 126.87% [1][3]. - The net cash flow from operating activities was -206.12 million yuan, a drastic decline of 257.03% compared to the previous year [1][3]. Financial Performance Summary - Revenue: 972 million yuan, down 25.50% from 1.30 billion yuan [3]. - Total profit: -33.86 million yuan, down 126.86% from 126.07 million yuan [3]. - Net profit attributable to shareholders: -33.77 million yuan, down 126.87% from 125.71 million yuan [3]. - Net profit excluding non-recurring items: -36.11 million yuan, down 110.61% from 340.26 million yuan [3]. - Net cash flow from operating activities: -206.12 million yuan, down 257.03% from 131.27 million yuan [3]. Company Background - Shenzhou Cell was listed on the Shanghai Stock Exchange on June 22, 2020, with an initial share issuance of 50 million shares at a price of 25.64 yuan per share [1][4]. - The total amount raised from the initial public offering was 1.28 billion yuan, with a net amount of 1.20 billion yuan after expenses [4][6]. - The company also conducted a private placement of A-shares in 2021, raising approximately 483.3 million yuan [4][5].

Group 1 - The core point of the news is that Shenzhou Cell's stock price increased by 5.01% to 55.09 CNY per share, with a trading volume of 102 million CNY and a turnover rate of 0.42%, resulting in a total market capitalization of 24.534 billion CNY [1] - Shenzhou Cell, established on April 23, 2007, and listed on June 22, 2020, is based in Beijing and focuses on the research and industrialization of biopharmaceutical products for various diseases, including malignant tumors, autoimmune diseases, infectious diseases, and genetic disorders [1] - The company's main business revenue is entirely derived from product sales, accounting for 100% of its income [1] Group 2 - From the perspective of fund holdings, Shenzhou Cell is the top holding of the Galaxy Quantitative Optimal Mixed A Fund (004250), which held 6,529 shares in the second quarter, representing 2.13% of the fund's net value [2] - The Galaxy Quantitative Optimal Mixed A Fund has a current scale of 17.7364 million CNY and has achieved a year-to-date return of 24.01%, ranking 3,463 out of 8,161 in its category [2] - The fund manager, Luo Bo, has a tenure of 15 years and 296 days, with the fund's total asset size at 2.75 billion CNY, achieving a best return of 165.8% during his tenure [2]

Core Viewpoint - Shenzhou Cell is planning to raise 600-900 million yuan through a private placement of A-shares to supplement working capital and support R&D efforts, with the controlling shareholder, Lhasa Ailike, subscribing to the entire issuance at a price of 36 yuan per share [1][2]. Fundraising Necessity and Sources - The fundraising is aimed at enhancing operational funds, ensuring R&D investments, and reducing operational and financial risks. Despite revenue growth from 2022 to the first half of 2025, the company faces significant funding needs in the biopharmaceutical and vaccine sectors, with cumulative losses reaching 3.863 billion yuan and a debt ratio of 97.03% as of June 30, 2025 [2]. - Lhasa Ailike's subscription will be financed through a combination of self-owned funds (approximately 440 million yuan) and borrowed funds, with Huanneng Guicheng Trust providing up to 600 million yuan at an interest rate of 5.8% to 7% [2]. Compliance and Stock Price Analysis - The issuance has complied with relevant decision-making procedures and disclosure obligations, aligning with legal regulations and company bylaws. Since the pricing date of June 6, 2025, the company's stock price has increased, reflecting industry trends and operational performance [3]. Previous Fundraising Projects - In the previous public offering, 99.52% of the raised funds were allocated to non-capital expenditures, with adjustments made to improve fund utilization efficiency and align with policy directions and company strategies [4]. Operational Performance Analysis - The core product, Anjia, experienced revenue and gross margin fluctuations due to centralized procurement, with sales revenue declining by 37.99% year-on-year in the first half of 2025 [5]. - R&D expenses have decreased recently as several major products have completed Phase III clinical trials, leading to reduced spending on clinical trial costs [6]. Pipeline Progress and Risks - As of June 30, 2025, the company has one recombinant protein drug and four antibody drugs approved for market, with several products in clinical and preclinical stages. However, there are inherent risks in new drug development, and the company cannot guarantee the timing or success of product approvals [7]. Sales Expense Increase - Sales expenses have risen annually due to new product launches and the expansion of the sales team, with promotional costs including professional service fees and patient welfare projects [9]. Asset and Liability Situation - The company's cash and interest income are well-matched, and there are no issues with fund occupation. The overall aging structure of accounts receivable is good, with sufficient provisions for bad debts [11][12]. - Inventory provisions have been adjusted reasonably, with a significant provision of 95.37% for COVID-19 vaccine products in 2023, which has since decreased [13]. Intangible Assets and Debt Risk - The increase in intangible assets is attributed to growth in R&D technology, and the company has established a robust financial risk management system to ensure debt repayment, despite an increase in borrowing [14][15]. Collaboration with Shiyao Group - The collaboration with Shiyao Group has been terminated, with related funds reclassified in accordance with accounting standards, and this has not adversely affected the company's operations [16].

Core Viewpoint - The financial performance of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. has shown significant fluctuations, with a notable decline in revenue and net profit due to price reductions from centralized procurement and medical insurance cost control measures. The company is also advancing its product pipeline but faces inherent risks in new drug development [2][3]. Group 1: Operating Performance - The company's operating revenue for the reporting period was 1,023.18 million yuan, 1,887.35 million yuan, 2,512.71 million yuan, and 519.74 million yuan, with net profits of -518.99 million yuan, -396.86 million yuan, 111.93 million yuan, and 64.06 million yuan respectively [2]. - In the first half of 2025, the company reported operating revenue of 972.02 million yuan and a net loss of -33.86 million yuan, marking a year-on-year decline of 37.99% in sales revenue due to the impact of centralized procurement and medical insurance cost control [2]. - Research and development expenses decreased in 2024 and the first half of 2025, primarily due to the completion of Phase III clinical trials for several products and other pipelines being in early stages [2][3]. Group 2: Asset and Liability Situation - As of June 30, 2025, the company had cash and cash equivalents of 302.87 million yuan, accounts receivable of 795.72 million yuan, inventory of 281.61 million yuan, and intangible assets of 176.20 million yuan [4]. - The company’s short-term borrowings amounted to 1,235.41 million yuan, with a total debt increase primarily for advancing research and industrialization projects and supplementing working capital [4]. - The company has a decreasing debt-to-asset ratio, with sufficient bank credit lines and a well-arranged repayment plan for short-term borrowings, indicating manageable debt repayment risks [4]. Group 3: Other Matters - As of June 30, 2025, the company had no significant financial investments, and there were no new or planned financial investments in the six months prior to the board resolution for this issuance [5]. - The company has timely and accurately transitioned construction in progress to fixed assets, with prepaid expenses mainly related to material procurement and service payments [5].

点击查看公告原文>> 登录新浪财经APP 搜索【信披】查看更多考评等级 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 9月5日，神州细胞收到上交所出具的《关于北京神州细胞生物技术集团股份公司向特定对象发行股票申 请文件的审核问询函》。10月15日，公司披露对该审核问询函的回复。 责任编辑：小浪快报 据公告，神州细胞会同相关中介机构对审核问询函所列问题进行研究落实，结合2025年半年度财务报告 更新申请文件，并按要求对有关问题说明论证。相关回复及申请文件已公开披露。 不过，公司本次向特定对象发行股票事项，尚需通过上交所审核，并获得中国证监会同意注册决定方可 实施。最终能否通过上交所审核并获得中国证监会同意注册及其时间，均存在不确定性。公司将及时履 ...

股票简称：神州细胞 股票代码：688520 北京神州细胞生物技术集团股份公司 2025 年度向特定对象发行 A 股股票 募集说明书 （修订稿） 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年十月 北京神州细胞生物技术集团股份公司 2025年度向特定对象发行A股股票募集说明书 声 明 本公司及全体董事、高级管理人员承诺募集说明书内容真实、准确、完整， 不存在任何虚假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并承担 相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证券监督管理委员会、上海证券交易所对本次发行所作的任何决定或意 见，均不表明其对申请文件及所披露信息的真实性、准确性、完整性作出保证， 也不表明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断 或保证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格 ...